Buyer questions · Use scenarios
Our whitening serum filing is ready, but based on current NMPA review trends, which parts are most likely to be rejected for correction, and will the timeline be extended?
A whitening serum is a special cosmetic under NMPA. The three most likely correction triggers: (1) mismatch among formula sheet, label, test report, and execution standard; (2) efficacy evidence tier below the claim tier (e. g. , using consumer-use test to back a whitening claim); (3) broken safety-assessment chain (missing raw-material supplier safety data). A correction request will extend the timeline; reserve a window for the longest possible in-vivo retest. No approval date can be promised.
1Four-Document Cross-Check
Any mismatch in net volume, pH, active-concentrate content, usage, shelf-life, or manufacturer across the formula sheet, label draft, test report, and execution standard is the first high-risk point reviewers check; complete a line-by-line cross-check before submission.
2Efficacy-Evidence Tier Alignment
A whitening or spot-removal claim must follow the special-cosmetic registration path; in-vivo efficacy trials provide the strongest evidence. If the claim is backed by consumer-use testing or literature data only, a correction is highly likely; proactively downgrade the claim before submission.
3Safety-Assessment Chain Integrity
Each raw material's supplier safety data (safety information code or equivalent) is a required link in the safety-assessment file; gaps here are a common reason for completeness rejection. Treat supplier safety-data submission as a gating condition at formula freeze, not as a last-minute task.
Follow-up questions
- Q:Can multiple rounds of materials be submitted after a correction notice?
- A:Treat it as a one-time response: address each point, answer only what is asked, do not expand scope; new issues introduced by the response are the common cause of a second round.
- Q:The product is already marketed overseas - can the foreign review file be reused directly?
- A:Domestic and overseas filings use different formats, terminology, and evidence standards; two independent document sets should be planned from the start. Any formula differences require a consistency explanation.
Updated 2026-09-18
Want this worked out for your category and target market? Send an inquiry